PreMD cholesterol test
This article was originally published in The Gray Sheet
Toronto-based PreMD files a 510(k) application seeking a broader claim for its Prevu POC noninvasive sterol test, the firm announces June 6. PreMD hopes the test, which measures cholesterol levels in the skin and was cleared in September for risk assessment of coronary artery disease in patients with a history of heart attack or evidence of artery blockage, will be cleared for patients without known or suspected disease. FDA is also reviewing a 510(k) application for Prevu LT, designed for use in the life insurance industry. Other cancer tests in development at PreMD include ColorectAlert, LungAlert and a breast cancer diagnostic...
You may also be interested in...
Non-invasive diagnostic test maker PreMD says it has the necessary data to support broader use of its PREVU POC skin cholesterol test in asymptomatic patients
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from India's Glenmark.
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.